Barts Cancer Institute (BCI), supported by the Pancreatic Cancer Research Fund, are working with Spirogen and ADC Therapeutics in finding a cure for pancreatic cancer from an unlikely source – foot and mouth disease. The virus, which wiped out more than six million...

      August was an exciting month at Barts Life Sciences as we selected projects for our second cohort of the CAP-AI programme. Watch this space for more details on these projects and how you can get involved this autumn. We’re also delighted to be...

Queen Mary University of London has developed the world’s first urine test for detecting pancreatic cancer, potentially improving survival rates by as much as 60%. The test has been developed to spot warning signs of the disease in the earliest stages. Often called...

    From the desk of CAP-AI data scientist Andrew Bard: Project title: Prediction of aortic changes from surveillance magnetic resonance imaging in congenital ascending aortic aneurysm The CAP-AI programme enables a wide range of projects, and facilitates...

Research by QMUL which assesses blood samples in the prognosis of prostate cancer, has been granted a European patent through Aim-listed liquid biopsy company, ANGLE plc. QMUL published research in Clinical Cancer Research in 2017 using ANGLE’s Parsortix® system...